Filing Details
- Accession Number:
- 0000950170-24-032990
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-18 17:45:14
- Reporting Period:
- 2024-03-14
- Accepted Time:
- 2024-03-18 17:45:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1674416 | Crispr Therapeutics Ag | CRSP | Biological Products, (No Disgnostic Substances) (2836) | 473173478 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1968317 | Raju Prasad | C/O Crispr Therapeutics 105 West First Street Boston MA 02127 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Acquisiton | 2024-03-14 | 10,000 | $0.00 | 10,000 | No | 4 | M | Direct | |
Common Shares | Disposition | 2024-03-15 | 3,524 | $72.69 | 6,476 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Restricted Stock Units | Disposition | 2024-03-14 | 10,000 | $0.00 | 10,000 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
30,000 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.